Sangamo initiated at BofA/MerrillBofA/Merrill analyst Qian Wang initiated Sangamo with a Buy and $24 price target saying it has one of the most advanced pipelines in the clinic using zinc finger protein technology. Wang said Sangamo has established partnerships with major players that validates the technology and expects multiple catalysts throughout 2H 2018 and beyond.Read more at: https://thefly.com/landingPage...(Source theFly) * This stock has been on our trading list for a while now. Will continue to look for trades in this name. $SGMO, Sangamo Therapeutics, Inc. / M30 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or posts.